Fabio D'amore

Via Giustiniani 2
Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.

Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.

Journal: Critical reviews in oncology/hematology

Published: September 03, 2025

Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT.

Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT.

Journal: Bone marrow transplantation

Published: April 25, 2025

Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study.

Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study.

Journal: Journal of clinical medicine

Published: November 07, 2024

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.

Journal: Frontiers in oncology

Published: April 26, 2023

Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia.

Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia.

Journal: British journal of haematology

Published: December 23, 2022

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".

Journal: Cancer medicine

Published: May 28, 2022

Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia.

Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia.

Journal: British journal of haematology

Published: February 10, 2022

Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications.

Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications.

Journal: European journal of haematology

Published: August 18, 2020

Second primary malignancy in myelofibrosis patients treated with ruxolitinib.

Second primary malignancy in myelofibrosis patients treated with ruxolitinib.

Journal: British journal of haematology

Published: July 26, 2020

Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.

Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: July 02, 2019

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.

Journal: Leukemia research

Published: July 16, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026